drugset / Trial / NCT05731908
A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2023-04-13
- Completion
- 2023-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vicadrostat | Small molecule | — | — |